Healthcare -
Biotechnology - NASDAQ - US
$ 6.55
3.47 %
$ 956 M
Market Cap
-1.79
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
89bio, Inc.
| Net Income | -367 M |
| Depreciation & Amortization | -9.14 M |
| Capital Expenditures | -15 K |
| Stock-Based Compensation | 20.6 M |
| Change in Working Capital | -14.5 M |
| Others | -19.3 M |
| Free Cash Flow | -368 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (367.1) | (142.2) | (102.0) | (90.1) | (49.5) | (57.4) | (16.2) |
| Depreciation & Amortization | (9.1) | 50 K | 65 K | 79 K | 60 K | 17 K | 6 K |
| Deferred Income Tax | 0 | 0.1 | 0 | (0.1) | 69 K | 20 K | 20 K |
| Stock Based Compensation | 20.6 | 16.1 | 10.4 | 8.7 | 3.8 | 0.4 | 0.1 |
| Other Operating Activities | 2.3 | (3.9) | 41 K | 1.5 | 0.5 | 30.6 | 1.0 |
| Change in Working Capital | (14.5) | 0.7 | 10.6 | 3.3 | (1.0) | 0.9 | 2.6 |
| Cash From Operations | (367.8) | (129.2) | (81.1) | (76.8) | (46.2) | (25.5) | (12.5) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | 15 K | 4 K | 7 K | 63 K | (0.1) | (0.1) | 39 K |
| Other Items | (40.8) | (123.0) | (33.9) | 7.2 | (106.7) | 0 | 0 |
| Cash From Investing Activities | (40.9) | (123.0) | (33.9) | 7.2 | (106.8) | (0.1) | 39 K |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0.4 | 0.3 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 9.3 | 3.0 | 0 | 20.0 | 0 | 0 | 100 K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 51.7 | 13.6 | 0.8 | 0.1 | 0.2 | 20.0 | 23.7 |
| Cash From Financing Activities | 218.6 | 513.1 | 117.8 | 23.9 | 157.9 | 107.7 | 23.8 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | (190.1) | 260.9 | 2.8 | (45.8) | 4.8 | 82.1 | 11.3 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (367.8) | (129.2) | (81.1) | (76.8) | (46.4) | (25.6) | (12.5) |